RxDoctor Payments Data

Helen Ashton, MD

Family Medicine · Oxnard, CANPI 1730619198

Payments from drug & device makers

$1,019in general payments, 2019–2025

Across 35 payments — averaging $29.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$265
  • Amgen$163
  • Novo Nordisk$145
  • AbbVie$103
  • Abbott$96
  • Agios Pharmaceuticals, Inc.$54
  • plus $194 from 6 others

What the payments were for

  • Food & beverage$92090%
  • Education$9910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,019 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$43,769
Medicare patients
90
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban31$38,208
TymlosAbaloparatide12$37,105
EliquisApixaban33$32,289
OzempicSemaglutide15$27,297
JardianceEmpagliflozin18$26,967
RybelsusSemaglutide24$26,545
TrulicityDulaglutide11$25,599
JanuviaSitagliptin Phosphate17$18,871
Atorvastatin Calcium278$1,864
Famotidine102$1,698
BreynaBudesonide/Formoterol Fumarate11$1,684
Levemir FlexpenInsulin Detemir11$1,444
Levothyroxine Sodium136$1,442
Losartan Potassium177$1,400
Estradiol23$1,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$145$53,84239 claims
PfizerEliquis$42$32,28933 claims
Lilly USA, LLCTrulicity$23$25,59911 claims
MerckJanuvia$24$18,87117 claims
AbbVieSynthroid$103$71312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →